心血管诊断领域的创新者Cardio Diagnostics Holdings Inc.与印度本土企业Aimil Ltd.及知名诊断服务商Dr. Lal Pathlabs Limited达成战略合作，共同在印度市场推出突破性冠心病风险评估方案——PrecisionCHD™检测。该合作将整合三方在基因检测、临床诊断及医疗网络方面的优势，为印度医疗系统提供更精准的预防性心血管健康管理工具。
PrecisionCHD™作为基于表观遗传学的前沿检测技术，能通过DNA甲基化分析评估个体冠心病发病风险。此次落地印度，标志着亚洲心血管疾病防控领域迈入个性化精准医疗新阶段。合作方计划通过Dr. Lal Pathlabs遍布全国的检测中心，逐步推广该技术至基层医疗机构。
印度作为心血管疾病高发国家，每年约有300万人死于相关病症。此次三方联盟不仅为当地患者提供更早期的风险干预窗口，也可能为Cardio Diagnostics的全球市场扩张战略奠定重要基石。业内观察人士指出，该合作模式或将成为跨国医疗科技企业与本土机构协同创新的范本。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.